Summary & Overview
HCPCS G9420: Non-Lung or Non-Primary NSCLC Specimen Site
HCPCS Level II code G9420 identifies pathology specimens originating from a site other than the lung or specimens that are not classified as primary non-small cell lung cancer. Nationally, this descriptor matters for correct specimen classification, claims adjudication, and ensuring diagnostic records accurately reflect the tumor origin when lung primary disease is not present. Clear use of G9420 assists in appropriate clinical coding and downstream analytics related to cancer staging and treatment planning.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of coding context, payer coverage considerations, and operational implications.
Readers will learn what G9420 represents clinically and administratively, which payers are commonly involved in coverage decisions, and the typical service settings where the code applies. The report covers benchmarks and policy-relevant points where available, clarifies clinical context for specimen classification, and identifies gaps where input data is not provided. Data not available in the input will be explicitly noted.
Billing Code Overview
HCPCS Level II code G9420 indicates a specimen site other than the anatomic location of the lung or a specimen that is not classified as primary non-small cell lung cancer. This code describes the origin or classification of a pathology specimen when the source is outside the lung or when the specimen cannot be categorized as a primary non-small cell lung cancer.
-
Service type: Pathology/Specimen Classification
-
Typical site of service: Outpatient pathology laboratories, hospital pathology departments, and diagnostic specimen processing centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a history of suspected metastatic lung malignancy undergoes tissue sampling when the available specimen is from a site other than the anatomic lung (for example, a pleural implant, supraclavicular lymph node, liver lesion, or bone metastasis) or when the pathology does not meet criteria for primary non-small cell lung cancer. Typical workflow: the oncology team identifies a nonpulmonary lesion on imaging or physical exam requiring biopsy to establish diagnosis, guide systemic therapy, or perform molecular testing. An interventional radiologist, surgical oncologist, thoracic surgeon, or general surgeon performs the biopsy or excision in an ambulatory surgery center, hospital outpatient department, or inpatient operating room depending on clinical acuity and complexity. Specimen is labeled with site of origin distinct from the lung, sent to pathology for histologic classification and immunohistochemistry, and if indicated forwarded for molecular testing (EGFR, ALK, PD-L1). Documentation includes indication, anatomic site sampled, biopsy technique, amount of tissue obtained, any complications, and pathology request for specific ancillary studies. Common payors for authorization and claims adjudication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity substantially exceeds that usually required for the procedure due to extensive dissection or unexpected difficulty at the nonpulmonary site |